Alkermes Elects Nancy Wysenski to Board of Directors

Posted: Published on May 16th, 2013

This post was added by Dr Simmons

DUBLIN--(BUSINESS WIRE)--

Alkermes plc (ALKS) today announced the election of Nancy J. Wysenski to the companys Board of Directors. Most recently serving as Chief Commercial Officer at Vertex Pharmaceuticals Incorporated, Ms. Wysenski has more than 35 years of healthcare experience, nearly 30 years of which have been in leadership and commercial roles in the biopharmaceutical industry.

We are very pleased to welcome Nancy to our Board. Nancy is an industry veteran with decades of experience in leading several of the most successful commercial operations in the business, said Richard Pops, Chief Executive Officer of Alkermes. Nancys exceptional grasp of the opportunities and challenges entailed in product launches, commercial development and operational growth will add significant strategic perspective as candidates from our pipeline portfolio, namely aripiprazole lauroxil and ALKS 5461, progress to the commercial stage.

During her tenure at Vertex, Ms. Wysenski was responsible for expanding and directing the companys sales, marketing, market research and sales operations activities for the companys first two commercial products, INCIVEK and KALYDECO. Under her leadership, these two products generated more than $1.5 billion in combined sales within the first 12 months, and INCIVEK achieved net sales of $1 billion in less than a year, faster than any previous pharmaceutical product.

Prior to joining Vertex in 2009, Ms. Wysenski was Chief Operating Officer of Endo Pharmaceuticals, responsible for sales, marketing, commercial operations, outsourced production, supply chain management, human resources and business development activities, as well as the successful integration of Indevus Pharmaceuticals, Inc. following Endos acquisition of the company. Ms. Wysenski was President and Chief Executive Officer of EMD Pharmaceuticals, Inc., the North American subsidiary of Merck KGaA, prior to joining Endo, and also served as EMDs Vice President of Commercial until 2001. Between 1984 and 1998, Ms. Wysenski held several sales-focused roles with Merck Human Health and Astra Merck, including Vice President of Field Sales for Astra Merck.

I am very excited to be joining Alkermes Board of Directors at a time when the company is evolving into a robust biopharmaceutical development company that is generating novel pipeline candidates with significant commercial opportunities, said Ms. Wysenski. Alkermes is on the cusp of very promising developments with late-stage product candidates, aripiprazole lauroxil and ALKS 5461, which represent significant opportunities for the company to provide patients, providers and payors with meaningful new treatment options to address serious diseases. It is an invigorating time to join the Board with the rapid progress at the company, and I look forward to sharing my insights and experiences with the management team.

Ms. Wysenski began her career in healthcare as a nurse in the Acute Psychiatry / Medical Teaching / Research Units at the Veterans Administration Medical Center in Cleveland. Ms. Wysenski serves on the Board of Directors of Reata Pharmaceuticals, Inc. and North Carolina Central Universitys Board of Trustees. She is a founder of the Research Triangle Park Chapter of the Healthcare Businesswomens Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomens Association.

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio. For more information, please visit Alkermes website at http://www.alkermes.com.

Forward-Looking Statements

Visit link:
Alkermes Elects Nancy Wysenski to Board of Directors

Related Posts
This entry was posted in MS Treatment. Bookmark the permalink.

Comments are closed.